Drug Update · Nephrology

FDA Approves Finerenone for CKD in T2D: Cuts Kidney Risk 18% in FIDELIO-DKD

July 09, 2026

Primary outcome event rates (FIDELIO‑DKD)

Finerenone 17.8% (504/2833) vs placebo 21.1% (600/2841) [1]

Primary endpoint hazard ratio

HR 0.82; 95% CI 0.73-0.93 (FIDELIO‑DKD) [1]

Key secondary CV endpoint

HR 0.86; 95% CI 0.75-0.99 (FIDELIO‑DKD) [1]

Trial size and follow-up

Randomized N=5,674 (finerenone N=2,833; placebo N=2,841); median follow-up 2.6 years [1][12]

Clinical Perspective

Adult patients with CKD associated with type 2 diabetes who remain at risk for progressive kidney disease and cardiovascular events are the population addressed by the approval; the data derive from randomized, placebo‑controlled trials in adults with CKD and T2D receiving background ACEi/ARB therapy ^[4]^[1]. The FIDELIO‑DKD results support finerenone for reducing the risk of CKD progression and major cardiovascular events when added to standard background therapy, with attention to hyperkalemia and renal function monitoring as described in the label ^[1]^[3]^[4]. How to integrate finerenone with concurrent renin‑angiotensin system blockade and potassium‑modifying therapies (and the optimal monitoring cadence in routine practice) remains a practical question.

Dr. Praveen Singh, MBBS, MD (General Medicine), DM (Nephrology) · Nephrology

The FDA approved finerenone (Kerendia) to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes on July 9, 2021. The approval was based in part on the FIDELIO‑DKD trial, in which finerenone lowered the primary composite kidney outcome to 17.8% versus 21.1% with placebo (hazard ratio, 0.82; 95% CI, 0.73-0.93) ^[1]^[4]^[2].

Clinical Context

Finerenone is a nonsteroidal, selective mineralocorticoid receptor antagonist (nsMRA) developed by Bayer and marketed as Kerendia ^[3]^[4]. The FDA prescribing information and label describe finerenone as a selective antagonist of the mineralocorticoid receptor that blocks MR-mediated effects in epithelial and nonepithelial tissues and is intended to address pathways thought to contribute to fibrosis and inflammation ^[4]. The program supporting its approval included the phase 3 FIDELIO‑DKD and FIGARO‑DKD trials in adults with CKD associated with type 2 diabetes, both randomized, double‑blind, placebo‑controlled multicenter studies testing finerenone added to background therapy that included ACE inhibitors or ARBs ^[4]. The FDA-approved indication covers reduction in the risks of kidney and cardiovascular outcomes in this population ^[3]^[4].

Key Findings

The FIDELIO‑DKD trial showed finerenone reduced the risk of the primary composite kidney outcome (kidney failure, a sustained decrease in eGFR of at least 40% from baseline, or death from renal causes) by 18% versus placebo (HR 0.82; 95% CI, 0.73-0.93) ^[1].
In FIDELIO‑DKD the primary outcome occurred in 504 of 2,833 patients (17.8%) in the finerenone group and 600 of 2,841 patients (21.1%) in the placebo group during a median follow-up of 2.6 years (P = 0.001) ^[1].
The trial also reported a key secondary cardiovascular composite (death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure) with events in 367 patients (13.0%) on finerenone versus 420 patients (14.8%) on placebo (HR 0.86; 95% CI, 0.75-0.99; P = 0.03) ^[1].
Overall adverse‑event frequency was reported as similar between groups in the trial report, with specific differences described below; background use of ACE inhibitors or ARBs was nearly universal in the trial population ^[1]^[4].

Safety & Tolerability

Hyperkalemia: rates and consequences were higher with finerenone; hyperkalemia occurred more often on finerenone than placebo and hyperkalemia‑related discontinuation occurred in 2.3% versus 0.9% (finerenone vs placebo) in FIDELIO‑DKD ^[1]^[3].
Hypotension: identified as an adverse reaction occurring more frequently on finerenone in pooled analyses (4.6% finerenone vs 3.0% placebo) ^[3].
Hyponatremia: identified as an adverse reaction occurring more frequently on finerenone in pooled analyses (1.3% finerenone vs 0.7% placebo) ^[3].
Worsening renal function (reported more frequently in heart‑failure studies): in heart‑failure trial data included in label material, events related to worsening renal function were more frequent with finerenone than placebo and led to more dose modifications in that population ^[3].

Study Design

FIDELIO‑DKD was a randomized, double‑blind, placebo‑controlled, multicenter phase 3 trial in adults with CKD associated with type 2 diabetes who were receiving a maximum tolerated labeled dose of an ACE inhibitor or ARB. The trial randomized 5,674 patients to finerenone (N = 2,833) or placebo (N = 2,841) with a median follow‑up of 2.6 years; the primary composite was time to kidney failure, sustained ≥40% decline in eGFR from baseline, or death from renal causes ^[1]^[4]. Additional pivotal data from FIGARO‑DKD informed the program and the label ^[4].

FAQ

Q1 What is finerenone (Kerendia) approved for?

Finerenone (Kerendia) is approved to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end‑stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes. The approved indication is explicit in the FDA label and prescribing information. Clinicians should consult current prescribing information for complete dosing guidance.

Q2 How does finerenone work?

Finerenone is a nonsteroidal, selective antagonist of the mineralocorticoid receptor (MR). According to the prescribing information, it blocks MR‑mediated effects in epithelial and nonepithelial tissues and is intended to counter MR overactivation that contributes to fibrosis and inflammation. This mechanism is described in the FDA labeling and clinical pharmacology summaries. Clinicians should consult current prescribing information for complete dosing guidance.

Q3 What is the recommended dose of finerenone (Kerendia)?

For CKD associated with type 2 diabetes the FDA‑approved starting dose is 10 mg or 20 mg orally once daily based on eGFR and serum potassium thresholds, with a target dose of 20 mg once daily after appropriate monitoring and titration. The label provides detailed tables for initiation and dose adjustment by eGFR and serum potassium and specifies monitoring intervals. Clinicians should consult current prescribing information for complete dosing guidance.

Q4 What are the most common side effects of finerenone?

Trial and label data identify hyperkalemia as a key adverse effect occurring more frequently on finerenone than placebo; pooled trial data showed hyperkalemia rates higher with finerenone and hyperkalemia‑related discontinuation (2.3% finerenone vs 0.9% placebo in FIDELIO‑DKD). Other adverse reactions reported more frequently with finerenone in pooled analyses include hypotension and hyponatremia; the label also documents events related to worsening renal function in heart‑failure populations. The FDA label and trial publications summarize monitoring recommendations and management considerations for these events. Clinicians should consult current prescribing information for complete dosing guidance.

FDA Approves Finerenone for CKD in T2D: Cuts Kidney Risk 18% in FIDELIO-DKD

FDA Approves Finerenone for CKD in T2D: Cuts Kidney Risk 18% in FIDELIO-DKD

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly clinical updates for Nephrology in your inbox.

Verified HCP Portal